| Smokers | p | Non-Smokers | p | |||
|---|---|---|---|---|---|---|
| Budesonide (n= 15 ) | Budesonide + Formoterol (n= 14 ) | Budesonide (n= 14 ) | Budesonide + Formoterol (n= 14 ) | |||
| FEV1 % pred | 96.1 ± 17.6 | 97.1 ± 17.7 | 0.91 | 93.2 ± 14.4 | 93.6 ± 12.5 | 0.85 |
| FVC % pred. | 116.7 ± 16.3 | 116.3 ± 15.5 | 0.74 | 103.0 ± 19.4 | 102.5 ± 15.6 | 0.98 |
| PEFam | 414 ± 72 | 430 ± 63 | 0.11 | 460 ± 101 | 467 ± 95 | 0.34 |
| PEFpm† | 429 ± 73 | 445 ± 61 | 0.11 | 464 ± 101 | 476 ± 96 | 0.08 |
| β2 agonist use† | 6.9 ± 9.2 | 5.9 ± 5.2 | 0.12 | 2.7 ± 4.0 | 3.5 ± 5.1 | 0.63 |
| Awakening† | 1.9 ± 4.2 | 1.3 ± 1.9 | 0.27 | 0.8 ± 1.3 | 0.6 ± 1.3 | 0.50 |
| Asthma episodes† | 5.3 ± 5.6 | 7.2 ± 6.6 | 0.016 | 4.2 ± 4.8 | 2.5 ± 2.4 | 0.009 |
| ACQ Score† | 1.1 ± 0.7 | 1.2 ± 0.7 | 0.78 | 0.8 ± 0.6 | 0.9 ± 0.7 | 0.89 |
| ACSS Score†† | ||||||
| Clinical | 84.7 ± 14.2 | 98.8 ± 16.5 | 0.66 | 87.0 ± 11.0 | 84.5 ± 21.5 | 0.69 |
| Physiological | 89.7 ± 14.2 | 91.2 ± 15.8 | 0.30 | 87.3 ± 14.5 | 89.1 ± 13.4 | 0.86 |
| Inflammatory | 66.2 ± 21.2 | 75.0 ± 13.7 | 0.13 | 80.0 ± 21.4 | 84.6 ± 16.6 | 0.26 |
| Global | 80.2 ± 8.9 | 81.9 ± 10.9 | 0.31 | 85.1 ± 10.5 | 86.7 ± 10.3 | 0.28 |
| AQLQ Score†† | ||||||
| Symptoms | 5.6 ± 0.8 | 5.4 ± 0.8 | 0.78 | 6.0 ± 1.0 | 5.9 ± 1.0 | 0.62 |
| Activities | 6.2 ± 0.6 | 6.1 ± 0.6 | 0.56 | 6.3 ± 0.6 | 6.3 ± 0.7 | 0.90 |
| Emotion | 6.5 ± 0.5 | 7.0 ± 3.5 | 0.65 | 6.3 ± 0.7 | 6.3 ± 0.9 | 0.58 |
| Stimuli | 5.9 ± 0.7 | 5.8 ± 0.8 | 0.87 | 6.1 ± 1.1 | 6.3 ± 0.7 | 0.42 |
| Global | 6.0 ± 0.6 | 6.0 ± 1.0 | 0.99 | 6.2 ± 0.8 | 6.2 ± 0.7 | 0.84 |